Free Trial
NASDAQ:STAB

Statera Biopharma (STAB) Stock Price, News & Analysis

Statera Biopharma logo
$0.0001 0.00 (0.00%)
As of 05/23/2025 02:45 PM Eastern

About Statera Biopharma Stock (NASDAQ:STAB)

Key Stats

Today's Range
$0.0001
$0.0001
50-Day Range
N/A
52-Week Range
$0.00
$0.13
Volume
256 shs
Average Volume
9,565 shs
Market Capitalization
$5,330.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. Statera Biopharma, Inc. is based in Fort Collins, Colorado.

Receive STAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Statera Biopharma and its competitors with MarketBeat's FREE daily newsletter.

STAB Stock News Headlines

Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time is about to validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.
Statera BioPharma Inc Ordinary Shares
See More Headlines

STAB Stock Analysis - Frequently Asked Questions

Statera Biopharma's stock was trading at $0.0001 at the beginning of the year. Since then, STAB stock has increased by 0.0% and is now trading at $0.0001.
View the best growth stocks for 2025 here
.

Shares of STAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Statera Biopharma investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT ().

Company Calendar

Today
5/24/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:STAB
Employees
20
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$5,330.00
Optionable
Not Optionable
Beta
0.10
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:STAB) was last updated on 5/25/2025 by MarketBeat.com Staff
From Our Partners